Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Purpose: Few studies have compared the performance of gene-expression profiling tests (e.g. Oncotype-Dx) to clinico-pathologic risk calculators (e.g. PREDICT 2.1, INFLUENCE 2.0, and CTS5) or tools that combine both (e.g. RSClin) in patients with early breast cancer (EBC). A large trial dataset was u...

Full description

Bibliographic Details

Published in:	Breast
Main Authors:	Ana-Alicia Beltran-Bless, Gregory R. Pond, Jane Bayani, Sarah L. Barker, Melanie Spears, Elizabeth Mallon, Karen J. Taylor, Annette Hasenburg, Christos Markopoulos, Luc Dirix, Elma Meershoek-Klein Kranenbarg, Cornelis J.H. van de Velde, Daniel W. Rea, Lisa Vandermeer, John Hilton, John M.S. Bartlett, Mark Clemons
Format:	Article
Language:	English
Published:	Elsevier 2025-10-01
Subjects:	Adjuvant Breast cancer Gene-expression profiling RSClin Clinical risk Prognostic
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977625005454